Skip to main content

Table 1 Baseline characteristics and homocysteine levels before and after treatment in stroke patients grouped according to treatment efficacy

From: A prospective cohort study of MTHFR C677T gene polymorphism and its influence on the therapeutic effect of homocysteine in stroke patients with hyperhomocysteinemia

 

Poor efficacy group (n = 59)

Effective efficacy group (n = 103)

P value

Gender, male (%)

51 (86.4%)

87 (84.5%)

0.734

Age, years

46.51 ± 13.7

57.7 ± 13.3

< 0.001

Stroke types

 Hemorrhagic, n (%)

34 (57.6%)

45 (43.7%)

0.088

 Ischemic, n (%)

25 (42.4%)

58 (56.3%)

 Hypertension, n (%)

55 (93.2%)

84 (81.6%)

0.041

 Diabetes mellitus, n (%)

17 (28.8%)

38 (36.9%)

0.269

 Abnormal lipid metabolism, n (%)

34 (57.6%)

75 (72.8%)

0.070

 Hyperuricemia, n (%)

10 (16.9%)

7 (6.8%)

0.042

HCY, μmol/L

 Before treatment

26.49 ± 15.75

21.88 ± 18.99

0.116

 After treatment

21.64 ± 10.81

12.42 ± 5.99

< 0.001

MTHFR C677T genotype

 CC, n (%)

1 (1.7%)

9 (8.7%)

< 0.001

 CT, n (%)

10 (16.9%)

45 (43.7%)

 

 TT, n (%)

48 (81.4%)

49 (47.6%)

Â